Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A David Burden

Showing results (21-30 of 55) with videos related to

Pageof 6
Sort By:
The Journal of Investigative Dermatology|January 19, 2005
The major psoriasis susceptibility locus PSORS1 is not a risk factor for late-onset psoriasisMichael Hugh Allen, Hahreen Ameen, Colin Veal, et al.
JAMA Dermatology|March 29, 2018
Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIRKayleigh J Mason, Jonathan N W N Barker, Catherine H Smith, et al.
The Journal of Investigative Dermatology|July 14, 2024
Spesolimab Reduces Inflammation in Generalized Pustular Psoriasis: Molecular Characterization of Flare Treatment in EFFISAYIL 1Ahmed Farag, Sudha Visvanathan, Hervé Bachelez, et al.
Human Genetics|June 26, 2007
Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasisFrancesca Capon, Paola Di Meglio, Joanna Szaub, et al.
Lancet (London, England)|September 22, 2023
Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trialAkimichi Morita, Bruce Strober, A David Burden, et al.
BMJ Open|March 31, 2021
Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flareSiew Eng Choon, Mark G Lebwohl, Slaheddine Marrakchi, et al.
American Journal of Human Genetics|August 16, 2011
Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasisAlexandros Onoufriadis, Michael A Simpson, Andrew E Pink, et al.
The Journal of Investigative Dermatology|August 22, 2018
Defining the Therapeutic Range for Adalimumab and Predicting Response in Psoriasis: A Multicenter Prospective Observational Cohort StudyNina Wilkinson, Teresa Tsakok, Nick Dand, et al.
The Journal of Investigative Dermatology|May 2, 2017
Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-AnalysisZarif K Jabbar-Lopez, Zenas Z N Yiu, Victoria Ward, et al.
The Journal of Investigative Dermatology|September 21, 2019
IL-36 Promotes Systemic IFN-I Responses in Severe Forms of PsoriasisMarika Catapano, Marta Vergnano, Marco Romano, et al.
Pageof 6

Showing results (21-30 of 55) with videos related to

Sort By:
Pageof 6
The Journal of Investigative Dermatology|January 19, 2005
The major psoriasis susceptibility locus PSORS1 is not a risk factor for late-onset psoriasisMichael Hugh Allen, Hahreen Ameen, Colin Veal, et al.
JAMA Dermatology|March 29, 2018
Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIRKayleigh J Mason, Jonathan N W N Barker, Catherine H Smith, et al.
The Journal of Investigative Dermatology|July 14, 2024
Spesolimab Reduces Inflammation in Generalized Pustular Psoriasis: Molecular Characterization of Flare Treatment in EFFISAYIL 1Ahmed Farag, Sudha Visvanathan, Hervé Bachelez, et al.
Human Genetics|June 26, 2007
Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasisFrancesca Capon, Paola Di Meglio, Joanna Szaub, et al.
Lancet (London, England)|September 22, 2023
Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trialAkimichi Morita, Bruce Strober, A David Burden, et al.
BMJ Open|March 31, 2021
Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flareSiew Eng Choon, Mark G Lebwohl, Slaheddine Marrakchi, et al.
American Journal of Human Genetics|August 16, 2011
Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasisAlexandros Onoufriadis, Michael A Simpson, Andrew E Pink, et al.
The Journal of Investigative Dermatology|August 22, 2018
Defining the Therapeutic Range for Adalimumab and Predicting Response in Psoriasis: A Multicenter Prospective Observational Cohort StudyNina Wilkinson, Teresa Tsakok, Nick Dand, et al.
The Journal of Investigative Dermatology|May 2, 2017
Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-AnalysisZarif K Jabbar-Lopez, Zenas Z N Yiu, Victoria Ward, et al.
The Journal of Investigative Dermatology|September 21, 2019
IL-36 Promotes Systemic IFN-I Responses in Severe Forms of PsoriasisMarika Catapano, Marta Vergnano, Marco Romano, et al.
Pageof 6